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ABSTRACT
Objectives To determine whether assessment of all moderate-to-severe symptoms at baseline
gives a more accurate evaluation of the treatment effect of ospemifene in vulvovaginal atrophy
(VVA) than the most bothersome symptom (MBS) approach.
Methods Data were pooled from two pivotal phase-III clinical trials evaluating the efficacy and
safety of oral ospemifene 60mg/day for the treatment of symptoms of VVA (n¼ 1463 subjects).
Symptoms of vaginal dryness, dyspareunia, and vaginal and/or vulvar irritation/itching reported as
moderate or severe at baseline were evaluated. Clinically relevant differences between ospemifene
and placebo were analyzed using a four-point severity scoring system and presented as
improvement, substantial improvement, or relief.
Results Subjects in these studies reported statistically significant improvement, substantial
improvement, and relief for vaginal dryness (p50.00001), dyspareunia (p50.001) and statistically
significant improvement and relief for vaginal and/or vulvar irritation/itching (p50.01) from
baseline to week 12 with ospemifene compared with placebo. A similar trend was observed for
women who reported substantial improvement of vaginal and/or vulvar irritation/itching.
Conclusions For drug registration purposes, the use of the MBS model is appealing because of its
simplicity and ease of scientific validation. However, the MBS model may underestimate the total
magnitude of the clinical benefit of ospemifene treatment for symptomatic women suffering from
VVA.
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Introduction
Vulvar and vaginal atrophy (VVA) is a chronic, progres-
sive medical condition which affects the majority of
postmenopausal women1–3. VVA is a consequence of the
decline in estrogen levels during menopause and is
associated with physiological changes of the vulval,
vaginal, and urogenital epithelia. Such changes give rise
to a number of genital and urinary symptoms. Genital
symptoms include dryness, dyspareunia, itching, irrita-
tion, and burning, whereas urinary symptoms include
urgency, increased frequency, nocturia, dysuria, accen-
tuated incontinence, and recurrent urinary tract infec-
tions2,4. Symptoms can vary in severity, ranging from
mild to severe discomfort, thus negatively impacting
sexual health and quality of life2,5. By postmenopause,
almost all women report at least one symptom, and
most report five or more, with 50% of women
experiencing vaginal discomfort attributable to VVA6–8.
Despite the availability of several treatment options for
VVA, satisfaction and compliance with available treat-
ments are low, with many women citing long-term
safety, lack of efficacy, and lack of convenience as
reasons for dissatisfaction9. There is therefore a need for
pharmacological treatment options that are convenient
to use and that are able to treat the multiple symptoms
associated with VVA.
The US Food and Drug Administration (FDA) has
published guidance outlining the conduct of clinical
studies for the treatment of VVA, specifying that a new
product is required to demonstrate efficacy at three co-
primary endpoints: namely a change in (1) maturation
index (decrease in the percentage of parabasal vaginal
cells and increase in the percentage of superficial vaginal
cells); (2) vaginal pH; and (3) severity of the patient-
reported most bothersome symptom (MBS), which are
derived from a select list of symptoms scored by
participants at baseline on a scale of 0–3 (0, none; 1,
mild; 2, moderate; 3, severe)10.
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Although the MBS metric may be simple in its
approach, by using both a simple four-step severity
scale and ensuring that each patient is only counted
once, it does have some limitations. The use of a
composite MBS score includes all treated participants in
the analysis, but is a function of any combination of
symptoms, and thus, symptom individuality is lost11.
However, by evaluating each individual symptom as an
MBS, a very selective patient population is created11,
resulting in a substantial reduction in the number of
patients included in the analysis12. In fact, when only
one symptom per woman is considered, the treatment
effect on approximately 60% of VVA symptoms is
ignored11,12. Furthermore, many patients with VVA
experience more than one moderate or severe symptom
but are restricted to choosing only one symptom as their
MBS. Therefore, the MBS metric may not permit a
meaningful subgroup analysis for each individual symp-
tom12. It has been proposed that a more meaningful
approach to determine treatment efficacy may be to
measure changes in all moderate-to-severe symptoms at
baseline instead of the MBS, which will involve counting
the number of symptoms rather than the number of
patients12. Although patients who show multiple symp-
toms would be counted more than once, this approach
may allow a more accurate evaluation of treatment
effects.
To test this hypothesis, the current pooled analysis
used data from two pivotal studies13–15 showing that
treatment with ospemifene was consistently associated
with greater clinically relevant improvements in the
severity of the MBSs of vaginal dryness or dyspareunia
compared with placebo. The objective of the analysis
was to evaluate the clinical relevance of ospemifene
treatment as defined by improvement, substantial
improvement, or relief, of all moderate or severe
symptoms of VVA at baseline, as has also been done
for MBS5. The current analysis considered vaginal
dryness, dyspareunia, and vaginal and/or vulvar irrita-
tion/itching, as they are the three most common
symptoms reported by women with VVA and are
recommended for the assessment of efficacy of treat-
ments for VVA10,12.
Methods
Patients and study design
The current analysis pooled data from two trials
evaluating the efficacy and safety of oral ospemifene
60mg/day compared with placebo for the treatment of
symptoms of VVA in 1463 postmenopausal women13–15.
The study designs and inclusion criteria are described in
detail elsewhere13–15. Both studies were multicenter,
randomized, double-blind, 12-week, phase-III studies in
postmenopausal women aged 40–80 years with the
following criteria of VVA: (1) 5% or less superficial cells
on the vaginal smear (maturation index); (2) vaginal
pH45.0; (3) at least one moderate or severe symptom of
VVA (Study 310; NCT00276094)13, or moderate-to-severe
vaginal dryness or dyspareunia (Study 821;
NCT00729469)14,15. Both studies were designed to com-
pare the effect of ospemifene versus placebo on the
symptom that was selected by the patient as their MBS
(co-primary endpoint), but also collected information on
the severity of other VVA symptoms as a secondary
endpoint14,15. As the secondary endpoints of all moder-
ate or severe symptoms at baseline in both studies were
collected in the same way, they were therefore
combined for this analysis (Table 1)14,15.
Both studies were approved by the institutional
review board and ethics committee for each site and
conducted according to the Declaration of Helsinki and
its amendments, and Good Clinical Practice. All patients
provided written informed consent before trial initiation.
Symptom severity was measured using a four-point
scoring system (none, 0; mild, 1; moderate, 2; and severe,
3); the mean changes from baseline, based on this
scoring system for the co-primary endpoints of vaginal
dryness and dyspareunia in each study, have been
reported elsewhere13–15, as have the clinically meaningful
differences between 60mg ospemifene and placebo5.
Data analyses
The current analysis focused on patients who received
either ospemifene 60mg/day or placebo in both studies
and includes a total of 1463 patients13–15. Analysis of
clinically meaningful differences to the patient’s condi-
tion was assessed by the concepts of improvement,
substantial improvement, or relief of symptoms in the
60-mg ospemifene group compared with placebo5,11.
Symptoms reported as moderate or severe at baseline
in either study, which included vaginal dryness, dyspar-
eunia, and vaginal and/or vulvar irritation/itching, were
selected for the present analysis. Efficacy analysis
included the change from baseline to week 12 in the
severity of symptoms: improvement was defined as a
reduction in one or more units on the four-point severity
scoring system5,11; substantial improvement was defined
as a reduction in two or three units on the four-point
severity scoring system, which, by default, only includes
subjects who had moderate or severe symptoms at
baseline, changing from severe to mild or none, and
moderate to none5; and relief was defined as having a
severity score at week 12 of mild or none (i.e. does not
signify a change, but records the final score)5,11.
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For missing values, the last observation carried
forward (LOCF) was used. Improvement, relief, and
substantial improvement were analyzed using the
Fisher’s exact two-sided test.
Results
Distribution of symptoms
Approximately one-fifth of the women who received
either ospemifene 60mg/day or placebo (23.9% and
17.7%, respectively) reported only one moderate or
severe symptom. Overall, 79.5% of women in both
studies combined had more than one symptom (two
symptoms: 47.3%; three symptoms: 23.5%; four symp-
toms: 7.1%) (Table 2). Of the 1332 women with moderate
or severe vaginal dryness, 40.2% reported it as their MBS.
Similarly, 75.7% of all women with moderate or severe
dyspareunia selected it as their MBS. However, since
vaginal and/or vulvar irritation/itching were not selected
to be analyzed as an MBS, the effect of ospemifene on
this symptom was not assessed via the MBS approach. It
was also found that, between screening and random-
ization, approximately 20% of women changed their
MBS selection. In total, in the current analysis the
number of moderate or severe symptoms assessed more
than doubled compared with the MBS approach (Table
1), as also described by other authors11,12.
Clinical relevance
The clinical relevance of the change in severity of
moderate or severe vaginal dryness, dyspareunia, and
vaginal and/or vulvar irritation/itching was assessed
using definitions of improvement, substantial improve-
ment, and relief (Figure 1). A significant proportion of
subjects reported an improvement in the moderate or
severe symptoms of vaginal dryness (72.9 vs. 57.6%;
p50.00001), dyspareunia (76.7 vs. 63.9%; p50.00001),
and vaginal and/or vulvar irritation/itching (80.3 vs.
69.4%; p¼ 0.0053) from baseline to week 12 with
ospemifene compared with placebo (Figure 1a). A
significant proportion of women reported a substantial
improvement in vaginal dryness (46.3 vs. 28.4%;
p50.00001) and dyspareunia (51.0 vs. 40.0%;
p¼ 0.0002), and a trend was seen for vaginal and/or
vulvar irritation/itching (51.8 vs. 43.5%; p¼ 0.0726)
(Figure 1b). Similarly, a significant proportion of subjects
reported relief for all three symptoms: vaginal dryness
(63.6 vs. 44.5%; p50.00001), dyspareunia (63.0 vs. 49.6%;
p¼ 0.0002), and vaginal and/or vulvar irritation/itching
(74.7 vs. 66.1%; p¼ 0.0393) from baseline to week 12
with ospemifene compared with placebo (Figure 1c).
Discussion
The current analysis showed that the clinical relevances
of VVA treatment were similar for moderate and severe
symptoms whether they were assessed by pooling all
symptoms or using the MBS method. Guidance from the
FDA requires that women enrolled in investigational
studies report the effect of a treatment on one symptom
of VVA, their MBS10. The current analysis also confirmed
that, by using the MBS approach, the effect of treatment
on half of VVA symptoms is not taken into consideration,
as previously shown by others11,12.
The MBS approach has some limitations, given that a
patient’s choice of MBS may change over time, as
reported in the current analysis. Because the MBS may
Table 1. Baseline frequency distribution of moderate-to-severe vulvovaginal atrophy symptoms included in this analysis and the most
bothersome symptom (MBS) by treatment group.
Number of women (in Studies 310 and 821)
60 mg ospemifene Placebo Total
MBS Moderate/severe MBS Moderate/severe MBS Moderate/severe
Dryness 278 676 258 656 536 1332
Dyspareunia 423 571 424 548 847 1119
Vaginal and/or vulvar
irritation/itching
– 149 – 248 – 397
Total 1383 2848
(–) denotes no data collected for that symptom
Table 2. Number of moderate-to-severe symptoms of vulvova-
ginal atrophy reported by women at baseline. Data are given as
n (%).
Number of
symptoms Study 310a Study 821b Total
0 6 (1.1%) 0 (0.0%) 6 (0.4%)
1 130 (23.9%) 163 (17.7%) 293 (20.0%)
2 252 (46.3%) 440 (47.9%) 692 (47.3%)
3 113 (20.8%) 231 (25.1%) 344 (23.5%)
4 33 (6.1%) 71 (7.7%) 104 (7.1%)
5 10 (1.8%) 14 (1.5%) 24 (1.6%)
Total 544 919 1463
aStudy 310 randomized patients to either ospemifene 30mg/day, ospemi-
fene 60mg/day or placebo; only data for patients receiving ospemifene
60mg/day or placebo are included for comparison with Study 821; bStudy
821 enrolled only patients with a most bothersome symptom of vaginal
dryness or dyspareunia
62 N. BRUYNIKS ET AL.
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Figure 1. Clinically relevant differences in the treatment of moderate or severe vaginal dryness, dyspareunia, and vaginal and/or
vulvar irritation/itching as assessed by (a) improvement, (b) substantial improvement, and (c) relief, in a pooled analysis of Studies 310
and 821. p Values for treatment comparisons (ospemifene 60 mg/day vs. placebo) from Fisher’s exact two-sided test. Improvement
was defined as a reduction in one or more units on the four-point severity scoring system (this includes patients whose baseline score
changed from severe to none, mild or moderate, from moderate to mild or none, and from mild to none). Substantial improvement
was defined as a reduction in two or three units on the four-point severity scoring system (this includes patients whose baseline score
changed from severe or moderate to none, or from severe to mild). Relief was defined as having a severity score at week 12 of mild or
none (i.e. does not signify a change, but records the final score). ****p5 0.00001; ***p5 0.0001; **p5 0.001; *p5 0.05; ns, not
significant.
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be selected from several of an individuals’ moderate or
severe symptoms, different patients may choose a
different symptom as their MBS despite similar severity.
A moderate or severe symptom that is chosen by one
patient as her MBS may not have the same weight for
another patient. Since the a priori distribution of women
entering any given trial with each symptom selected as
the MBS cannot be known, this poses statistical chal-
lenges, and information regarding effects on less com-
monly selected symptoms cannot be determined due to
the small subgroup sample size1. Considering the effect
of all moderate or severe symptoms at baseline may
therefore be more informative. The simplicity of the MBS
approach in measuring only one symptom per subject is
attractive as it avoids ‘double-counting’ of trial subjects.
However, it does not take into account those women
with more than one severe troubling symptom at
baseline.
The way that VVA symptoms are assessed is particu-
larly relevant for clinical practice as postmenopausal
women with VVA often experience multiple symp-
toms4,16 and several of these may be self-rated as
moderate to severe. The current analysis was the first of
its kind to assess the effect of ospemifene on all
moderate or severe symptoms of VVA for all patients
in the study. It is important to note that a substantial
placebo response was observed for some of the
outcomes (up to 69.4%). Although large placebo
responses are not uncommon in studies with patient-
reported outcomes as endpoint, in the current data set
the change from baseline in the placebo group may
have been partly due to the use of a non-hormonal
lubricant, provided for use as needed throughout the
studies. Despite a decrease in lubricant use in the
ospemifene group from baseline compared with
the placebo group13–15, ospemifene 60mg still resulted
in a statistically significant difference with placebo in
eight out of nine analyses. The analysis of all moderate
or severe symptoms of vaginal dryness and dyspareunia
at baseline was consistent with prior evidence that
showed the effectiveness of ospemifene 60mg/day in
the treatment of VVA, as assessed by the MBS approach5.
It demonstrates consistency in the effect of ospemifene
60mg/day in the postmenopausal VVA population.
Additionally, the current pooled analysis assessing the
clinical relevance of ospemifene on symptoms of VVA
confirms the robustness of the MBS approach for all
moderate or severe symptoms of VVA at baseline. For
drug registration purposes, the use of the MBS model is
appealing because of its simplicity and ease of scientific
validation, as shown in the current study. Nevertheless,
the MBS model may underestimate the total magnitude
of the clinical benefit to symptomatic women. Therefore,
we suggest using the two models concurrently in clinical
trials to maximize the information on a product for
prescribers.
Conclusion
Ospemifene 60mg/day consistently showed a greater
improvement, substantial improvement, or relief than
placebo at baseline for all moderate or severe symptoms
of vaginal dryness, dyspareunia, and vaginal and/or
vulvar irritation/itching. Although for drug registration
purposes the MBS model is required, both models
should be used in clinical trials to maximize information
on the product to aid prescribers. Well-planned studies,
utilizing an assessment of the effect of treatment on a
broad range of moderate-to-severe symptoms of VVA,
will provide a more comprehensive assessment of drug
efficacy, with the ultimate aim being to minimize and
manage symptoms, and improve quality of life in
women undergoing menopause.
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